Artificial intelligence (AI) software developer Viz.ai will use its Viz Recruit platform to help enroll patients in the National Institute of Health-funded Pulmonary Embolism-Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial.
The trial will explore the efficacy of catheter-directed therapy for patients at intermediate risk of PE compared with the use of anticoagulants alone and will enroll 500 patients across 30 to 50 sites, according to the firm.
